Association of BDNF and MMP-9 single-nucleotide polymorphisms with the clinical phenotype of schizophrenia

Lihong Pan¹*, Zhonghai Cao²*, Lianghu Chen¹, Min Qian¹ and Yuzhong Yan²*

¹Pudong Nanhui Mental Health Center, Shanghai, China, ²People's Hospital of Datong County, Datong, China, ³Department of Research, Shanghai University of Medicine and Health Sciences, Affiliated Zhoupu Hospital, Shanghai, China

Objective: Schizophrenia is a highly polygenic psychiatric disorder; however, the complex genetic architecture underlying the pathogenesis remains elusive. Brain-derived neurotrophic factor (BDNF), a neurotrophin, and matrix metalloproteinase 9 (MMP-9), a gelatinase B, are the promising candidate genes for schizophrenia. To shed new light on the relationship between the single-nucleotide polymorphisms (SNPs) of BDNF and MMP-9 and the clinical variability of schizophrenia phenotype, this study aims to evaluate the relationship, and provide more definitive evidence for the relationship with various clinical features of schizophrenia.

Methods: A case-control association study was performed, and one hundred and five subjects of Chinese Han population were enrolled, including 55 schizophrenia patients (SP) and 50 healthy controls (HC). The BDNF rs6265 196 G > A and MMP-9 rs3918242 –1562C > T SNPs were genotyped using PCR-RFLP assay. The Positive and Negative Syndrome Scale (PANSS) was used to assess the clinical symptoms of patients with schizophrenia.

Results: Compared with HC, the frequency of SP carrying BDNF rs6265 GG/GA genotype was significantly higher than HC, and the frequency of SP carrying MMP-9 rs6265 AA genotype was significantly lower than HC (p < 0.01). With regards to MMP-9 rs3918242 –1562C > T SNP, no significant difference was observed between the control and SP. BDNF GG genotype showed significantly higher PANSS and positive symptoms score than GA and AA genotypes (P < 0.01). MMP-9 CC genotype showed significantly higher PANSS and general score than CT and TT genotypes (P < 0.05).

Conclusion: BDNF rs6265 196 G > A and MMP-9 rs3918242–1562C > T SNPs are related to the clinical features of schizophrenia and could be a useful biomarker for the changes, remission or deterioration of clinical status of schizophrenia.

Keywords: schizophrenia, BDNF, MMP-9, single-nucleotide polymorphisms, clinical phenotype
Introduction

Schizophrenia (SZ) is a highly polygenic psychiatric disorder with complex genetic architecture which affects about 1% of the general population worldwide, and it stimulates extensive research on the pathophysiology of this psychiatric disorder. A large amount of evidence suggests that insufficient neurotrophic supply of cortical neurons may be a potential factor in the pathophysiology of SZ, because normal brain development, maturation and function require adequate neurotrophic support (1, 2).

Brain derived neurotrophic factor (BDNF) is a member of the neurotrophic factor family. It is a key regulator of synaptic plasticity, which affects various brain functions, including cognition (3). Mature BDNF is initially synthesized as a precursor protein proBDNF. After signal peptide cleavage, proBDNF is transformed into mature BDNF by extracellular protease, such as matrix metalloproteinase-9 (MMP-9) (4). Unbalanced expression of brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) may affect neurogenesis, synaptic plasticity, learning and memory ability (4). Therefore, they can be regarded as diagnostic biomarkers. The report also showed that during the pathological process of the study, BDNF parameters decreased and MMP-9 expression increased and a negative correlation between them was noted (5). Pooled evidence suggested that genetic determinants could be related to SZ (6, 7). Converging lines of proof suggested that BDNF 196G > A SNPs and MMP-9 −1562C > T may be associated with SZ (6, 8–10). However, findings of earlier studies on the relationship of these SNPs with SZ are contradicting and it has not been definitively figured out which of these SNPs is associated with SZ.

In order to clarify the relationship between BDNF and MMP-9 single nucleotide polymorphisms and clinical variability of SZ phenotype, this study was aimed to evaluate the relationship between them and provide more conclusive evidence for their correlation with various clinical features of SZ.

Materials and methods

Subjects

This study group (n = 105) recruited 55 schizophrenia patients (SP) and 50 healthy controls (HC) from November 2018 to July 2021. All subjects enrolled were unrelated Han Chinese people. The diagnosis of schizophrenia was assigned by two independent psychiatrists based on the ICD-10 criteria. The group consisted of inpatients and outpatients. At the time of examination all patients were stabilized (no acute psychosis). The healthy control (HC) were recruited from the local health examination center. In addition, age-, gender- and smoking status matched healthy subjects who were ruled out the presence of a current/past psychiatric disorder, were recruited.

Exclusion criteria for patients were age < 18 years, serious medical or surgical illness, previous episode of psychosis due to substance abuse, and psychotic symptomatology within a clearly diagnosed affective or borderline personality disorder. For healthy controls, exclusion criteria were age < 18 years, current or past psychiatric disorder, family history of any psychiatric disorder, head trauma, neurological illness, serious medical or surgical illness, or substance abuse. Detailed medical information, such as demographics, sociodemographic characteristics, and medical conditions were obtained from all subjects. This study was approved by the Ethics Committee of Pudong Nanhui Mental Health Center, Shanghai, and either patients or their guardians signed informed consents.

Clinical evaluation

Diagnosis and review of psychiatric case records were independently examined and assessed by at least two trained psychiatrists. Symptoms of schizophrenia case records were independently examined and assessed by at least two trained psychiatrists. Symptoms of schizophrenia were evaluated using the Positive and Negative Syndrome Scale (PANSS). The measurement of each patient's psychopathology was repeated twice to take the average value by two trained psychiatrists who were blind to the clinical status.

Genotyping

Venous blood was collected from all subjects. Serum was separated and stored at −80 °C until further analysis. Genomic DNA was extracted using QIAamp DNA Blood Kit (Qiagen, USA). The genotypes were determined using PCR-RFLP assay. A set of primers was designed from previously published articles (11, 12). Genotyping of the SNPs was analyzed by the Shanghai Major Biotechnology Co. Ltd. (www.majorbio.com).

Statistical analyses

Statistical analyses were carried out using GraphPad Prism 6 software. Differences in clinical characteristics between patients and controls were analyzed using the Pearson's chi-square for categorical variables. Data were presented as mean ± standard deviation (SD) for continuous variables if normally distributed and compared by independent samples Student's t-test. Data was analyzed using one-way analysis of variance (ANOVA) with post-hoc comparisons. Fisher's exact test was used to analyze the significance of a difference between the proportions. A P-value of <0.05 was considered to be statistically significant.
Results

Demographic and clinical features

Demographic and clinical features for the subjects are shown in Table 1. There were no statistically significant differences regarding age ($P = 0.33$), gender ($P = 0.78$), smoking ratio ($P = 0.74$) and BMI ($P = 0.64$) between SZ patients and HC. The comparisons revealed less education for SZ patients than in the HC ($P = 0.02$). The antipsychotic treatment of the SZ patients are also listed in the table.

Association between BDNF and MMP-9 gene SNPs and SZ patients

The allele frequencies and genotype distributions of BDNF and MMP-9 gene SNPs are presented in Table 2. Concerning the TABLE Demographic and clinical characteristics of SZ patients and healthy controls.

|        | SZ ($N = 55$) | HC ($N = 50$) | $\chi^2$ | p-value |
|--------|--------------|--------------|----------|---------|
| Age    | 33.22 ± 9.58 | 35.11 ± 10.13| 0.98     | 0.33    |
| Gender (M/F) | 29/26 | 25/25 | 0.08 | 0.78 |
| Education (years) | 5.32 ± 2.99 | 6.73 ± 3.26 | 2.31 | 0.02 |
| Smoking ratio (%) | 30.90 | 28.00 | 0.11 | 0.74 |
| BMI (kg/m2) | 21.16 ± 3.12 | 20.89 ± 2.76 | 0.47 | 0.64 |
| Age of onset (years) | 27.12 ± 10.18 | 9.19 ± 6.41 |        |        |

Antipsychotic treatment

Olanzapine (N) | 33
Risperidone (N) | 18
Aripiprazole (N) | 3
Chlorpromazine equivalents (mg/day) | 503.55 ± 132.11

BDNF rs6265 196 G $>$ A SNP, the distribution of genotypes GG, GA and AA, were 32.73, 43.64, and 23.64% in SZ, respectively, whereas they were 10.00, 28.00, and 62.00% in HC, respectively. A statistically significant difference was indicated ($P < 0.01$) with the patients carrying a significantly higher frequency of the GG/GA genotypes and a lower frequency of the AA genotype in comparison to HC.

With regards to MMP-9 rs3918242 $>$ -1562C $>$ T SNP, the distribution of genotype CC, CT and TT, was 58.18, 30.91, and 10.91% in SZ, respectively, whereas they were 54.00, 32.00, and 14.00% in HC, respectively. It was suggested that there was no significance between the controls and SZ patients.

Relationship between BDNF and MMP-9 genotypes and clinical features of SZ patients

As shown in Table 3, there was no significant difference between the BDNF and MMP-9 genotypes with regards to age of onset and duration of illness. Concerning the genotypes of BDNF, the results indicated that GG genotype showed significantly higher PANSS ($P < 0.01$) and positive symptoms score ($P < 0.01$) than GA and AA genotypes, and in comparison with GA genotype, AA genotype also showed significant lower scores. On the other hand, the negative symptoms score ($P = 0.21$) and general score ($P = 0.53$) did not differ significantly among the three genotypes. As for the genotypes of MMP-9, the results indicated that CC genotype showed significantly higher PANSS ($P = 0.03$) and general score ($P = 0.02$) than CT and TT genotypes, but not in either positive ($P = 0.52$) or negative symptoms scores ($P = 0.49$).

Discussion

Notwithstanding numerous groups endeavoring to examine the association between the BDNF rs6265 196 G $>$ A and MMP-9 rs3918242 1562C $>$ T SNPs and susceptibility to SZ,
### TABLE 3 Relationship between BDNF and MMP-9 genotypes and clinical features of SZ patients.

|               | Age of onset (years) | Duration of illness (years) | PANSS Positive symptoms score | Negative symptoms score | General score |
|---------------|----------------------|-----------------------------|-------------------------------|-------------------------|---------------|
| **BDNF rs6265** |                      |                             |                               |                         |               |
| GG (N = 18)   | 25.11 ± 8.67         | 10.23 ± 5.17                | 75.26 ± 4.11                  | 23.36 ± 4.53            |               |
| GA (N = 24)   | 26.22 ± 8.13         | 9.51 ± 4.29                 | 72.02 ± 4.38                  | 20.54 ± 4.11            |               |
| AA (N = 13)   | 28.92 ± 7.76         | 8.51 ± 4.09                 | 69.22 ± 3.89                  | 17.23 ± 5.08            |               |
| **MMP-9 rs3918242** |                  |                             |                               |                         |               |
| CC (N = 32)   | 26.56 ± 7.45         | 9.77 ± 4.42                 | 75.10 ± 5.36                  | 22.08 ± 6.03            |               |
| CT (N = 17)   | 27.67 ± 8.86         | 9.23 ± 4.03                 | 72.01 ± 4.55                  | 21.55 ± 5.09            |               |
| TT (N = 6)    | 29.11 ± 6.89         | 8.92 ± 3.56                 | 69.51 ± 4.89                  | 19.16 ± 5.28            |               |

* p < 0.05 GA vs. GG; ** p < 0.001; *** p < 0.000 and |p < 0.05 AA vs. GA; |p < 0.05 CT vs. CC; |p < 0.05 TT vs. CT.

TABLE 3 Relationship between BDNF and MMP-9 genotypes and clinical features of SZ patients.

- **BDNF rs6265** 196 G > A

  |               | Age of onset (years) | Duration of illness (years) | PANSS Positive symptoms score | Negative symptoms score | General score |
|---------------|----------------------|-----------------------------|-------------------------------|-------------------------|---------------|
| GG (N = 18)   | 25.11 ± 8.67         | 10.23 ± 5.17                | 75.26 ± 4.11                  | 23.36 ± 4.53            |               |
| GA (N = 24)   | 26.22 ± 8.13         | 9.51 ± 4.29                 | 72.02 ± 4.38                  | 20.54 ± 4.11            |               |
| AA (N = 13)   | 28.92 ± 7.76         | 8.51 ± 4.09                 | 69.22 ± 3.89                  | 17.23 ± 5.08            |               |

- **MMP-9 rs3918242** 1562 C > T

  |               | Age of onset (years) | Duration of illness (years) | PANSS Positive symptoms score | Negative symptoms score | General score |
|---------------|----------------------|-----------------------------|-------------------------------|-------------------------|---------------|
| CC (N = 32)   | 26.56 ± 7.45         | 9.77 ± 4.42                 | 75.10 ± 5.36                  | 22.08 ± 6.03            |               |
| CT (N = 17)   | 27.67 ± 8.86         | 9.23 ± 4.03                 | 72.01 ± 4.55                  | 21.55 ± 5.09            |               |
| TT (N = 6)    | 29.11 ± 6.89         | 8.92 ± 3.56                 | 69.51 ± 4.89                  | 19.16 ± 5.28            |               |

* p < 0.05 GA vs. GG; ** p < 0.001; *** p < 0.000 and |p < 0.05 AA vs. GA; |p < 0.05 CT vs. CC; |p < 0.05 TT vs. CT.

BDNF and MMP-9 gene SNPs are the most intensively studied identified genes are potential risk factors in schizophrenia. Animal studies have shown that the role of BDNF and MMP-9 genes as risk alleles or regulators of pathological synaptic plasticity of SZ. To further clarify the role of BDNF and MMP-9 genes in the pathogenesis of SZ, we carried out this case-control association study between BDNF and MMP-9 gene rs6265 and rs3918242 SNPs. We reported a significant difference in the distribution of BDNF and MMP-9 gene rs6265 and rs3918242 SNPs between SZ patients and control group, which provided evidence for the significance of BDNF and MMP-9 gene rs6265 and rs3918242 SNPs in the pathogenesis of SZ. Especially, the T allele showing a higher transcriptional activity than the C allele.
Despite the fact that numerous studies have been carried out on the assessment of the roles of BDNF and MMP-9 genotypes in association with clinical presentation, the results have become more contentious (18, 19). In this study, it was shown that the genotypes could play a critical role in SZ phenotype and contribute to the clinical expression. We found that significantly different PANSS and positive symptoms score were demonstrated among the genotypes of BDNF between SZ patients and HC. In line with our observations, Neves-Pereira et al. (20) also found an association between the BDNF rs6265 SNPs and the clinical presentation of schizophrenia on a Scottish population. It has been suggested that BDNF rs6265 genotype in hippocampus and inferior marginal medial prefrontal cortex may affect NMDA receptor-mediated neurotransmission and plasticity, which is related to the generation of positive or negative symptoms of schizophrenia (21). In addition, more and more evidence shows that BDNF rs6265 changes the clinical manifestation and genetic risk structure of schizophrenia, which may be achieved by affecting the clinical manifestation and treatment response (22). It has been suggested that more severe / chronic schizophrenia may be associated with allele (G), while less severe schizophrenia may be associated with allele (A) (10, 23, 24). Our data is consistent with the results presented above. Due to the lack of strong evidence and small sample size, studies describing the correlation between BDNF rs6265 and schizophrenia are still contradictory.

On the basis of Chinese Han population in this report, the assessment of the clinical significance of MMP-9 rs3918242 genotypes was also studied in the pathogenesis of SZ. Based on the data of this study, and in line with previous findings (7), MMP-9 1562 C/C genotype was considered as an independent predictor of the severity and was assessed by the positive and negative syndrome scale (PANSS), affirming association between MMP-9 genotypes and schizophrenia. Our results further support the hypothesis that MMP-9 could also play a critical role in the pathogenesis of SZ. Although in this study, we did not analyze the direct correlations between BDNF and MMP-9 genotypes, we assumed that there might be a compensated interaction between them as was previously reported (4). Taken together, our results suggested that the BDNF rs6265 196 G > A and MMP-9 rs3918242 −1562C > T SNPs could play a key role in the phenotype of SZ and contribute to the clinical presentation of SZ by altering a range of clinical features, including symptomatology.

The BDNF rs6265 196 G > A and MMP-9 rs3918242 −1562C > T SNPs are the most extensively studied genetic modifications in the psychopathology of SZ. However, it was clearly demonstrated in this report that BDNF rs6265 196 G > A and MMP-9 rs3918242 −1562C > T SNPs were related to the clinical phenotypes of SZ and could be useful biomarkers predicting the phenotypic expression and prognosis of SZ patients. It still remains contradictory in the absence of strong evidence, besides ethnic heterogeneity, sample size etc., which still need further investigation. In the absence of strong evidence, this is still contradictory. Our observation needs a confirmation through a large population study as the small sample size used for this study was a major limitation.

Conclusion

The analysis of SNPs in the present study shows that BDNF rs6265 196 G > A SNP could be a biomarker for the differentiation of SZ patients and could be involved in the pathogenesis of SZ. Differences in genotype distribution of BDNF and MMP-9 might be responsible for the phenotypes of SZ which provide evidence on the pathophysiology of SZ, and it could eventually lead to better therapy.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Pudong Nanhui Mental Health Center, Shanghai. The patients/participants provided their written informed consent to participate in this study.

Author contributions

YY: study conception, design, conceptualization, and drafting of the manuscript. LP and LC: patients recruitment and clinical monitoring. YY and ZC: conducting the biochemical and genotyping investigations. LC and ZC: acquisition of data. MQ and ZC: analysis and interpretation of data. LP, ZC, and YY: critical revision of the manuscript. All authors have approved the final version of the submitted manuscript.

Funding

This study was supported by grants from Medical Discipline Construction Project of Pudong Health Committee of Shanghai (Grant No. PWYgts2021-05), the Research Grant for Science and Technology Commission of Pudong, Shanghai (Grant No. PKJ2019-Y61), and Shanghai University of Medicine and Health Science (Grant No. SFP-22-21-17-024). The funder had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Tejeda GS, Diaz-Guerra M. Integral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies. Int J Mol Sci. (2017) 18:268. doi: 10.3390/ijms18020268
2. Arabiska J, Margulis A, Strzelecki D, Wysokiński A. Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia? Nord J Psychiatry. (2019) 73:512–21. doi: 10.1080/08039488.2019.1608126
3. Lu B, Martinowich. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp. (2008) 289:119–29. doi: 10.1002/9780470751251.ch10
4. Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. (2013) 556:37–41. doi: 10.1016/j.neulet.2013.09.059
5. Romash IR, Vynnyk MI. Peculiarities of brain-derived neurotrophic factor and matrix metalloproteinase-9 expression dynamics in patients with paranoid schizophrenia depending on the duration of the disease. Wiadomosci lekarskie. (2021) 74:2728–32. doi: 10.36740/WLek202111108
6. Bienkowski P, Samochowiec J, Pelka-Wysiecka J, Grywacz A, Skibinska M, Isiarczewska A, et al. Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype. Pharmaceut Res. (2015) 32:1308–12. doi: 10.1007/s11095-015-1952-6
7. Ali FT, Abd El-Azeem EM, Hamad MA, Ali MAM, Abd Al-Kader NM, Hassan EA. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. (2017) 188:98–109. doi: 10.1016/j.schres.2017.01.016
8. Rybakowski JK, Skibinska M, Kapeloski P, Kaczmarek L, Hausser J. Functional polymorphism of the matrix metalloproteinase-9 (MMP9) gene in patients with schizophrenia. Schizophr Res. (2009) 109:90–3. doi: 10.1016/j.schres.2009.02.005
9. Lu W, Zhang C, Li Z, Li Z, Wu Z, Fang Y. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J Mol Neurosci. (2012) 47:507–10. doi: 10.1007/s12031-012-9750-4
10. Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet. (2012) 131:1187–95. doi: 10.1007/s00439-012-1150-x
11. Wang CK, Xu MS, Ross CJ, Lo R, Procyrhn RM, Vila Rodriguez F, et al. Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system. Int J Methods Psychiatr Res. (2015) 24:235–44. doi: 10.1002/mpr.1475
12. El Samanoudy A, Monir R, Badawy A, Ibrahim L, Farag K, El Baz S, et al. Matrix metalloproteinase-9 gene polymorphism in hepatocellular carcinoma patients with hepatitis B and C viruses. Genet Mol Res. (2014) 13:8025–34. doi: 10.4238/2014.September.29.15
13. Ikegami T, Bundo M, Murata Y, Kasai K, Kato T, Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J Hum Genet. (2013) 58:434–8. doi: 10.1038/jhg.2013.65
14. Fu X, Wang J, Du J, Sun J, Baranova A, Zhang F. BDNF gene’s role in schizophrenia: from risk allele to methylation implications. Front Psychiatry. (2020) 11:564277. doi: 10.3389/fpsyt.2020.564277
15. Gratacos M, González JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry. (2007) 61:911–22. doi: 10.1016/j.biopsych.2006.08.025
16. Han H, He X, Tang J, Liu W, Liu K, Zhang J, et al. The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res. (2011) 190:163–4. doi: 10.1016/j.psychres.2011.04.026
17. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. (1999) 99:1788–94. doi: 10.1161/01.CIR.99.14.1788
18. Bakirhan A, Yalcin Sahiner S, Sahiner IV, Safak Y, Goka E. Association of serum brain derived neurotrophic factor with duration of drug-naive period and positive negative symptom scores in drug naive schizophrenia. PLoS ONE. (2017) 12:e0189373. doi: 10.1371/journal.pone.0189373
19. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. (2008) 32:1308–11. doi: 10.1016/j.pnpbp.2008.04.007
20. Neves-Pereira M, Cheung IK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry. (2005) 10:208–12. doi: 10.1038/mp.2004.157
21. Pattwell SS, Bath KG, Perez-Castro R, Lee FS, Chao MV, Ninan J. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J Neurosci. (2012) 32:2410–1. doi: 10.1523/JNEUROSCI.5205-11.2012
22. Schweiger JI, Bilek E, Schafer A, Braun U, Moessnang C, Harneit A, et al. Effects of BDNF Val66Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans. Neuropsychopharmacol. (2019) 44:590–7. doi: 10.1038/s41386-018-0248-9
23. Golimbet VE, Korovaisveva GI, Abramova LI, Kasparov SV, Uvarova LG. [Association between the Val66Met polymorphism of brain-derived neurotrophic factor gene and schizophrenia in Russians]. Mol Biol. (2005) 42:599–603. doi: 10.1134/S0026893300400079
24. Pelka-Wysiecka J, Wroński M, Jasieczwicz A, Grywacz A, Tyburza P, Kucharska-Mazur J, et al. BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in polish sample. Pharmacol Rep. (2013) 65:1185–93. doi: 10.1134/S003327991317476-2

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Frontiers in Psychiatry